Is Protalix BioTherapeutics, Inc

In health-care stocks news, Protalix BioTherapeutics ( PLX ) shares were up pre-market Thursday after the company reported it swung to a FY16 net loss of $0.29 per share from a profit of $0.61 per share in FY15, but beat the average of two analysts for a loss of $0.38 per share as provided by Capital IQ. Protalix BioTherapeutics, Inc. has a 52-week low of 0.26 and a 52-week high of 1.48.

The company's ATR (Average True Range) is 0.63.

Analysts estimated $-0.1/share for the previous Quarter, where Protalix BioTherapeutics, Inc.

For the current quarter, the highest estimate analysts provided is 1.5 Million and the lowest is 900 Million. According to them, the median (average) EPS the company could deliver is -0.11/share.

The stock has Return on Assets (ROA) of 0 percent.

Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) topped its 52-week high price of $1.48 on Mar 13, 2017 and 52-Week Low Price of $0.26 on Dec 13, 2016.

More news: Dontari Poe gets the same amount of money as Bennie Logan

The Stock had a 1 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 1 and 1 respectively. They now have a United States dollars 1 price target on the stock. This scale runs from 1 to 5 where 1 represents Strong Buy and 5 represents Sell. While the actual EPS the company reported in the same quarter previous year was 0.77/share.

09/06/2016 - Protalix BioTherapeutics, Inc. had its "buy" rating reiterated by analysts at Jefferies. The company has Beta Value of 0 and ATR value of 0.13.

2 analysts projected Price Targets for Protalix BioTherapeutics, Inc.

The stock's price switched up 30.47% 20-Days Simple Moving Average, added 85.86% from 50-Days Simple Moving Average and rose 129.11% from 200 Days Simple Moving Average. They now have a Dollars 3.5 price target on the stock. Full-year profit views are for Protalix BioTherapeutics, earn -$0.38 in current year and grow profits by almost -162.3% over last year's earnings of $0.61. (PLX) reported Q2 earnings loss of -$0.11, missing consensus estimates of -$0.08.

Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) has the market capitalization of $203.9 Million.

Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) performance during the last one year Improved 54.84 percent, while its year to date (YTD) performance showed a Positive trend of 220 percent. The stock now shows its YTD (Year to Date) performance of 217.78 percent while its Weekly performance value is 31.19%. Post-earnings, PLX stock ranged between $0.59 and $0.65 after opening the day (08/09/2016) at $0.64. The Return on Equity (ROE) value stands at 0%.